

a.) Amendment to the Specification:

Please amend the paragraph starting at page 14, line 25 and ending at page 15, line 8 to read as follows.

As shown in Fig. 1, duration of convulsion was significantly extended ($p < 0.001$; Student's t-test) ($p < 0.001$; Student's t-test) in the group treated with reserpine and administered with solvent as compared with a non-treated group. On the other hand, in a group administered with the test compound to which the compound 1 or 3 was administered, a significant shortening action was noted in terms of duration of convulsion as compared with the group which was treated with reserpine and administered with solvent ($p < 0.01$; Aspine-Welch test).

Please amend the paragraph at page 18, lines 22-23 to read as follows.

***: statistically significant difference where $p < 0.001$ (Student's t-test)
 $p < 0.001$ (Student's t-test)

Please amend the paragraph at page 21, lines 10-18 to read as follows.

WitepsolTM H15 (manufactured by Dynamite Nobel) (678.8 g) and 290.9 g of WitepsolTM E75 (manufactured by Dynamite Nobel) are ~~melted at 40 to 50~~ melted at 40 to 50°C. The compound 4 (2.5 g), 13.6 g of potassium primary phosphate and 14.2 g of sodium secondary phosphate are uniformly mixed with the above and dispersed therein. After that, the mixed/dispersed product is filled in suppository molds made of plastics

followed by gradual cooling to prepare suppositories for anus (each preparation contained 2.5 mg of the active ingredient).